Home

Mesothelioma

Mesothelioma Treatment

Mesothelioma Specialists

Clinical Trials

Managing Your Care

Veterans Resources

Sunitinib (Sutent) for Mesothelioma

Brand named Sutent, Sunitinib is a receptor tyrosine kinase inhibitor (RTKI) used to treat renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). It is also in clinical trials for mesothelioma treatment. The drug was approved on January 26th of 2006, and is the first cancer fighting drug to be approved for two different indications at the same time. This medication is widely prescribed by doctors and has become the de facto treatment for RCC and GIST. Sunitinib operates by inhibiting the signaling in cells including platelet-derived growth factor receptors and vascular endothelial growth factor receptors which cause tumor formation and growth. The effect is that the growth of tumors is slowed and the cancerous cells die.

Sutent is administered orally, and the common dosage cycle is once daily for a period of four weeks with a two week break between cycles. A dietary requirement while taking Sutent is to avoid eating grapefruit or drinking grapefruit juice as it will cause adverse reactions. While most patients experience few or manageable side effects, less than ten percent of patients have had heart failure. Some of the drug's other side effects include:

 

If any of the following side effects are experienced, you should contact your doctor immediately:

 

 

To receive a FREE Mesothelioma Web information packet** or to make a request, please fill out the following form :













Contact Us













**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376